REMARKS

Claim 1 is amended so as to define n as 2. Claim 3 has accordingly been canceled without prejudice.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "**Version With Markings To Show Changes Made**."

Action on this application is awaited.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____
Leonard C. Mitchard
Reg. No. 29,009

LCM:lks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

Page 1, line 1, please amend the first paragraph to read as follows:

This application is a continuation of application Serial No. 08/894,833, filed August 29, 1997, which is a 371 of PCT/SE97/01150, filed June 26, 1997, the entire content of which is hereby incorporated by reference in this application.

IN THE CLAIMS

1. (Amended) A compound of formula I,



I

wherein

one of R^1 and R^2 represents a structural fragment of formula Ia



Ia

and the other represents R^4;

Z represents O or $N(R^5)$;

R^3 represents one or more optional substituents selected from OH, halo, cyano, nitro, $C(O)OR^6$, C_{1-6} alkoxy or C_{1-6} alkyl (which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group) or $N(R^7)R^8$;

R^4 represents H, OH, halo, cyano, nitro, $C(O)OR^6$, C_{1-6} alkoxy or C_{1-6} alkyl (which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group) or $N(R^7)R^8$;

Ar^1 represents phenyl, C_{1-3} alkylphenyl, C_{1-3} alkyldiphenyl, C_{3-7} cycloalkyl, C_{1-3}-alkyl-C_{3-7}-cycloalkyl, C_{1-3}-alkyl-di-C_{3-7}-cycloalkyl, naphthyl, C_{1-3} alkylnaphthyl, thienyl, imidazolyl or isoxazolyl, all of which may be substituted by one or more substituent selected from OH, halo, cyano, nitro, $C(O)OR^6$, C_{1-6} alkoxy or C_{1-6} alkyl (which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group) or $N(R^7)R^8$;

R^5 represents H, C_{1-6} alkyl, phenyl or C_{1-3} alkylphenyl (which three latter groups are optionally substituted and/or terminated by one or more substituent

selected from OH, halo, cyano, nitro, $C(O)OR^9$, $C(O)N(R^{10})R^{11}$, $P(O)(R^{12})R^{13}$, $P(O)(OR^{14})OR^{15}$, $S(O)_2(R^{16})R^{17}$, $S(O)_2N(R^{18})R^{19}$, C_{1-6} alkoxy or C_{1-6} alkyl (which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group) or $N(R^{20})R^{21}$);

Y represents O, S, S(O), $S(O)_2$ or $N(R^{22})$;

R^{10} and R^{11} independently represent H, OR^{23}, $C(O)R^{24}$, $OC(O)R^{25}$, $C(O)OR^{26}$, C_{1-4} alkyl, (which latter group is optionally substituted and/or terminated by one or more substituent selected from C_{1-4} alkyl, OR^{27}, $N(R^{28})R^{29}$, $C(O)OR^{30}$, $C(O)N(R^{31})R^{32}$, $P(O)(R^{33})R^{34}$, $P(O)(OR^{35})OR^{36}$ and $S(O)_2N(R^{37})R^{38}$), $\cdot(CH_2CH_2O\cdot)_pR^{39}$ or, together with the nitrogen atom to which they are attached, form a C_{4-7} nitrogen-containing, aromatic or non-aromatic, ring which ring may contain a further heteroatom or group (as appropriate) selected from O, S and $N(R^{40})$ and may further be substituted by one or more substituent selected from $C(O)R^{41}$, $C(O)OR^{42}$ or $C(O)N(R^{43})R^{44}$;

R^{28}, R^{29}, R^{30}, R^{31}, R^{32} and R^{40} independently represent H or C_{1-6} alkyl, which latter group is optionally substituted and/or terminated by one or more substituent selected from $C(O)R^{45}$, $C(O)OR^{46}$ or $C(O)N(R^{47})R^{48}$;

at each [occurance] occurrence, R^6, R^7 and R^8 independently represent H or C_{1-4} alkyl;

R^9, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{25}, R^{26}, R^{27}, R^{33}, R^{34}, R^{35}, R^{36}, R^{37}, R^{38}, R^{39}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47} and R^{48} independently represent H or C_{1-4} alkyl;

n represents [0, 1,] 2[, 3 or 4];

p represents 1, 2, 3, 4, 5 or 6; and

B represents a structural fragment of formula Ib, Ic, Id or Ie



Ib



Ic



Id



Ie

wherein

X^1 and X^2 independently represent a single bond or CH_2;

or a pharmaceutically acceptable salt thereof.

4. (Amended) A compound of formula I, as defined in [any one of the preceding claims] claim 1, wherein R^2 represents a structural fragment of formula Ia and R^1 represents R^4.

5. (Amended) A compound of formula I, as defined in [any one of the preceding claims] claim 1, wherein Z represents O or $N(R^5)$, in which latter case R^5 represents C_{1-6} alkyl terminated by $C(O)N(R^{10})R^{11}$.

6. (Amended) A compound of formula I, as defined in [any one of the preceding claims] claim 1, wherein R^3 is not present, or represents methyl, chloro or methoxy.

7. (Amended) A compound of formula I, as defined in [any one of the preceding claims] claim 1, wherein Ar^1 represents substituted phenyl.

8. A compound of formula I, as defined in [any one of the preceding claims] claim 1 wherein Y represents O.

9. A compound of formula I, as defined in [any one of the preceding claims] claim 1 wherein B represents a structural fragment of formula Ib.

23. (Amended) A pharmaceutical formulation including a compound as defined in [any one of Claims 1 to 22] claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

24. (Amended) A compound as defined in [any one of Claims 1 to 22] claim 1, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

25. (Amended) A compound as defined in [any one of Claims 1 to 22] claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition where inhibition of thrombin is required.

26. (Amended) A compound as defined in [any one of Claims 1 to 22] claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment of thrombosis.

27. (Amended) A compound of formula I as defined in [any one of Claims 1 to 22] claim 1, or a pharmaceutically acceptable salt thereof, for use as an anticoagulant.

28. (Amended) The use of a compound I as defined in [any one of Claims 1 to 22] claim 1, or a pharmaceutically acceptable salt thereof as active ingredient in the manufacture of a medicament for the treatment of a condition where inhibition of thrombin is required.

30. (Amended) The use of a compound as defined in [any one of Claims 1 to 22] claim 1, or a pharmaceutically acceptable salt thereof, as active ingredient in the manufacture of an anticoagulant.

31. (Amended) A method of treatment of a condition where inhibition of thrombin is required which method comprises administration of a therapeutically effective amount of a compound as defined in [any one of Claims 1 to 22] claim 1, or a pharmaceutically acceptable salt thereof, to a person suffering from, or susceptible to, such a condition.